Sword Diagnostics Microbiology  
Company Profile Technology Products Support News Contact Us
 
 
News Media Center

Sword Diagnostics Announces Availability of Proprietary Detection Technology for Ultrasensitive Immunoassays

Chicago, IL - Jan 14, 2010 – Sword Diagnostics announced today the launch of its proprietary Raman detection system for ultrasensitive immunoassays. The system provides researchers with greater sensitivity which enables more accurate testing of low abundance markers. These increases in performance could aid researchers in basic and clinical science research, drug discovery, and clinical diagnostics development.

“We find the resolution at low concentrations to be an exciting benefit in our ovarian cancer and infertility research,” said Professor Judith Luborsky, Ph.D, Associate Dean for Research, College of Health Sciences, Director, Laboratory for Ovarian Cancer Research and Director, Rush Proteomics & Biomarkers Core Research Facility at Rush University Medical Center. “The technology was easily integrated into existing tests with minimal optimization and provided excellent improvements. In fact, we have included Sword technology in several grants we are currently applying for.”

“We are pleased with the positive reception our technology has received from the market. The key opinion leaders have found it particularly useful for highly sensitive ELISAs,” said Dave Dingott, founder and CEO of Sword Diagnostics. “The Raman plate reader allows current ELISA users to continue using their 96-well format, making conversion to our technology extremely simple and cost effective.”

About Sword Diagnostics
Sword Diagnostic’s mission is to improve existing immunoassays by providing additional sensitivity to currently available antibody-based test as well as allowing researchers to monitor new markers that are not readily detectable with current technology. This may lead to earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer’s disease. Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays. The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry. The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.

Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com
 
 
  U.S. Patent Office Issues Sword Diagnostics Patent for Highly Sensitive Immunodetection Technology

Chicago, IL - Dec 14, 2009 – Sword Diagnostics, Inc. is pleased to announce that the United States Patent Office (USPTO) has issued patent number 7,599,057 titled “ Method and Apparatus for Detection of Biological Organisms using Raman Scattering” to the company. The patent covers the core technology which focuses on improved sensitivity and specificity.

“The issuance of this patent supports the underlying strategy as we move forward with our continued development and commercialization” said Dave Dingott, CEO and President of Sword Diagnostics. “The feedback from our immunoassay customers validates the high degree of need in the market for a technology that delivers improved sensitivity without compromising in cost or complexity of the test.”

About Sword Diagnostics
Sword Diagnostic’s mission is to improve existing medical diagnostic tests by providing additional sensitivity to each currently available antibody-based test as well as allowing clinicians to monitor new markers that are not detectable with current technology. This will allow earlier and more accurate diagnosis of diseases such as cancer, cardiovascular disorders, and Alzheimer’s disease. Better diagnosis results in simpler treatments with more positive outcomes for patients and less costs.

Sword markets its technology for biomarker measurement for pharmaceutical drug discovery and academic life science researchers and will partner to develop clinical diagnostics assays.

The technical solution is an immunoassay detection system that uses Raman spectroscopy and a proprietary chemistry. The system extends the sensitivity over current detection technologies while being easily incorporated into assays that use a peroxidase-based detection system.

Contact:
Dave Dingott, President
Tel: 708-563-9166 x221
ddingott@sworddiagnostics.com
www.sworddiagnostics.com
 
 
 
 
Sword Diagnostics 2008©All Rights Reserved Graphic Design and Web Development by Graphic Advance